So it looks like the Medivation guys are good business negotiators, and most of the rest of biomed companies settle for much less good terms. The Medivation up front payment of $225M was fantastic. By comparison the schedule of payments the post you link to lays out nickles and dimes the biomed out for many years (nickles and dimes relative to their huge R&D budgets needed to support the programs).
What CLDX needs is some massive up front payments, to help in two ways:
1) To run up the stock, so that they can raise money through equity against the higher share price